



## SOCIAL / DIGITAL TOOLKIT

# 2022 U.S. Generic and Biosimilar Medicines Savings Report

As this report demonstrates, generic and biosimilar drugs continue to drive savings. The U.S. health care system, including patients, employers, and taxpayers, saved \$373 billion in 2021 by using FDA-approved generic and biosimilar drugs. With 91% of Rx filled, but only 18% of how much the United States spends on drugs, these findings reinforce the critical importance of the generic and biosimilar industry to America's patients. We encourage you to share the key findings with your social network.

## #GRxBiosimsSavingsReport

## STAY UP-TO-DATE

Find legislation in your area and send a message to your lawmaker to protect your access to affordable generic and biosimilar medicines.

- AAM Website: [accessiblemeds.org](https://accessiblemeds.org)
- AAM Action Center: [takeaction.accessiblemeds.org](https://takeaction.accessiblemeds.org)

## FOLLOW AAM ON SOCIAL MEDIA



## FOLLOW THE BIOSIMILARS COUNCIL



# 2022 U.S. GENERIC AND BIOSIMILAR MEDICINES SAVINGS REPORT

2022 U.S. Generic & Biosimilar Medicines Savings Report: <https://bit.ly/AAMSavingsReport>

## TAKE ACTION

- Follow and share AAM's Twitter posts especially those using the hashtag [#GRxBiosimsSavingsReport](#)
- Learn more about the issues on the [AAM](#) and [Biosimilars Council](#) advocacy pages
- Learn about advocacy campaigns in the [AAM](#) and [Biosimilars Council](#) Action Centers

# MESSAGE

We encourage you to include the hashtag [#GRxBiosimsSavingsReport](#) in your tweets and tag [@accessiblemeds](#) and [@biosimilarscouncil](#) in all posts so we can share your message!

# SOCIAL IMAGES

Click on each image to download. All images are accessible via [Dropbox](#).

# HASHTAGS

[#GRxBiosimsSavingsReport](#)

[#PatientAccess](#)

[#Generics](#)

[#GenericDrugs](#)


[#GenericMedicines](#)

[#Biosimilars](#)

[#Biosimilar](#)

[#DrugPricing](#)

If you need assistance, please contact AAM Senior Marketing Director Erica Klinger at:  
[Erica.Klinger@accessiblemeds.org](mailto:Erica.Klinger@accessiblemeds.org)



## TWITTER

- New data from the [@accessiblemeds](https://twitter.com/accessiblemeds) **#GRxBiosimsSavingsReport** shows that each **#Medicare** enrollee saved \$2447 per year through the use of **#generic** and **#biosimilar** medicines—\$119B for the system as a whole—in 2021 alone. Read more: <https://bit.ly/AAMSavingsReport> **#patientaccess** **#drugpricing**



## FACEBOOK / LINKEDIN

- New data from AAM's **#GRxBiosimsSavingsReport** shows that each **#Medicare** enrollee saved \$2447 per year through the use of **#generic** and **#biosimilar** medicines—\$119 billion for the system as a whole—in 2021 alone. Read more: <https://bit.ly/AAMSavingsReport> **#patientaccess** **#drugpricing**

## TOP 10 GENERIC AND BIOSIMILAR SAVINGS BY CONDITION IN 2021

CONDITION	TOTAL SAVINGS (PRIMARY CONDITION + COMORBIDITIES)
Heart Disease	\$96.7 Billion
Mental Illness	\$59.7 Billion
Diabetes	\$56.7 Billion
Epilepsy	\$37.4 Billion
Cancer	\$17.9 Billion
Allergies and Asthma	\$12.4 Billion
HIV/AIDS	\$5.8 Billion
Alzheimer's disease	\$5.5 Billion
Chronic Obstructive Pulmonary Disease (COPD)	\$5.3 Billion
Crohn's & Colitis	\$3.3 Billion

Source: IQVIA, National Sales Perspectives, Dec 2021.




TWITTER

- [@accessiblemeds](https://twitter.com/accessiblemeds) [#GRxBiosimsSavingsReport](https://twitter.com/GRxBiosimsSavingsReport) shows that in 2021, [#generics](https://twitter.com/generics) and [#biosimilars](https://twitter.com/biosimilars) generated \$97B in savings for patients with [#heartdisease](https://twitter.com/heartdisease), \$60B for patients treating [#mentalhealth](https://twitter.com/mentalhealth), and \$57B for persons living with [#diabetes](https://twitter.com/diabetes). View full report: <https://bit.ly/AAMSavingsReport>



FACEBOOK / LINKEDIN

- AAM's [#GRxBiosimsSavingsReport](https://twitter.com/GRxBiosimsSavingsReport) shows that in 2021, [#generics](https://twitter.com/generics) and [#biosimilars](https://twitter.com/biosimilars) generated \$97 billion in savings patients with [#heartdisease](https://twitter.com/heartdisease), \$60 billion for patients treating [#mentalhealth](https://twitter.com/mentalhealth), and \$57 billion for persons living with [#diabetes](https://twitter.com/diabetes). View full report: <https://bit.ly/AAMSavingsReport>




## TWITTER

- 91% of the 6.4B prescriptions filled in 2021 were for **#generics** and **#biosimilars**, however that 91% accounted for only 18% of spending on Rx medicines. View the full **#GRxBiosimsSavingsReport** report from @accessiblemeds: <https://bit.ly/AAMSavingsReport> **#patientaccess** **#drugpricing**
- While spending on brand drugs increased in 2021, spending on **#generic** meds declined again, continuing a multi-year trend of **#deflation** for **#generics** of more than 5% annually, even while **#inflation** affects most other consumer goods. <https://bit.ly/AAMSavingsReport> **#GRxBiosimsSavingsReport**



## FACEBOOK / LINKEDIN

- 91% of the 6.4 billion prescriptions filled in 2021 were for **#generics** and **#biosimilars**, however that 91% accounted for only 18% of spending on Rx medicines. View the full **#GRxBiosimsSavingsReport** report from AAM: <https://bit.ly/AAMSavingsReport> **#patientaccess** **#drugpricing**
- While spending on brand drugs increased in 2021, spending on **#generic** meds declined again, continuing a multi-year trend of **#deflation** for **#generics** of more than 5% annually, even while **#inflation** affects most other consumer goods. Read more: <https://bit.ly/AAMSavingsReport> **#GRxBiosimsSavingsReport**




**TWITTER**

- The average copay for **#generic** drugs in 2021 was only \$6.16, while the average copay for brand-name drugs was \$56.12. View the full **#GRxBiosimsSavingsReport** report from **@accessiblemeds**: <https://bit.ly/AAMSavingsReport> **#patientaccess #drugpricing**



**FACEBOOK / LINKEDIN**

- The average copay for **#generic** drugs in 2021 was only \$6.16, while the average copay for brand-name drugs was \$56.12. View the full **#GRxBiosimsSavingsReport** report from AAM: <https://bit.ly/AAMSavingsReport> **#patientaccess #drugpricing**



## TWITTER

- In 2021 alone, **#generic** & **#biosimilar** medicines generated a record \$373B in savings for the U.S. healthcare system & nearly \$2.6T over the past decade. View report: <https://bit.ly/AAMSavingsReport> **#generics** **#biosimilars** **#patientaccess** **#affordablemedicines** **#GRxBiosimsSavingsReport**



## FACEBOOK / LINKEDIN

- In 2021 alone, **#generic** and **#biosimilar** medicines generated a record \$373 billion in savings for the U.S. healthcare system & nearly \$2.6 trillion over the past decade. View full report: <https://bit.ly/AAMSavingsReport> **#generics** **#biosimilars** **#patientaccess** **#affordablemedicines** **#GRxBiosimsSavingsReport**

**PERCENT OF NEW GENERICS COVERED BY MEDICARE PART D AND COMMERCIAL PLANS BY FORMULARY YEAR**

Launch year	2016		2017		2018		2019		2020		2021		2022	
	M	C	M	C	M	C	M	C	M	C	M	C	M	C
2016	22%	46%	31%	68%	63%	72%	58%	72%	60%	76%	62%	78%	61%	90%
2017			12	58	25	73	58	73	65	76	65	76	64	89
2018					17	39	27	49	51	59	54	60	54	84
2019							31	44	59	60	72	61	72	88
2020									21	55	41	66	60	90
2021											23	86	46	89

● MEDICARE PART D (M) ● COMMERCIAL (C)

Source: Analysis of Medicare Part D formulary data from CMS and commercial market formulary data from Managed Markets Insight & Technology, LLC.




TWITTER

- New analysis from @accessiblemeds #GRxBiosimsSavingsReport shows that it takes 3 yrs. for new #genericmedicines to be covered by 50% of #Medicare Rx plans, meaning that #seniors pay more for longer than they should. Read more: <https://bit.ly/AAMSavingsReport> #patientaccess



FACEBOOK / LINKEDIN

- Analysis from AAM’s #GRxBiosimsSavingsReport shows that it takes 3 years for new #genericmedicines to be covered by 50% of #Medicare Rx plans, meaning that #seniors pay more for longer than they should. Read more: <https://bit.ly/AAMSavingsReport> #patientaccess




TWITTER

- Despite representing 91% of prescriptions dispensed in the US, **#generic** and **#biosimilar** medicines account for only 3% of total health care spending. Read more in **@accessiblemeds** **#GRxBiosimsSavingsReport**: <https://bit.ly/AAMSavingsReport>



FACEBOOK / LINKEDIN

- Despite representing 91% of prescriptions dispensed in the US, **#generic** and **#biosimilar** medicines account for only 3% of total health care spending. Read more in AAM's **#GRxBiosimsSavingsReport**: <https://bit.ly/AAMSavingsReport>




## TWITTER

- On average, **#biosimilar** sales prices are more than 50% lower at launch than the price of its brand competitor. **#Biosimilars** saved \$13B since 2015 (\$7B in 2021 alone). Read more in **@accessiblemeds @BiosimsCouncil #GRxBiosimsSavingsReport** <https://bit.ly/AAMSavingsReport>



## FACEBOOK / LINKEDIN

- On average, **#biosimilar** sales prices are more than 50% lower at launch than the price of its brand competitor. **#Biosimilars** saved \$13 billion since 2015 (\$7 billion in 2021 alone). Read more in AAM's **#GRxBiosimsSavingsReport**: <https://bit.ly/AAMSavingsReport>



- Good news for #patientaccess from @accessiblemeds @biosimscouncil #GRxBiosimsSavingsReport: there're nearly 100 #biosimilar products under development, an almost 50% increase over the last 4 years. Read more: <https://bit.ly/AAMSavingsReport> #GRxBiosimsSavingsReport



- Good news for #patientaccess from AAM's #GRxBiosimsSavingsReport: there are nearly 100 #biosimilar products under development, an almost 50% increase over the last 4 years. Read more: <https://bit.ly/AAMSavingsReport> #drugpricing #patientaccess #GRxBiosimsSavingsReport